HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bermekimab

targets interleukin-1alpha

Also Known As:

CA-18C3; CV-18C3; RA-18C3; T2-18C3; xilonix

Networked: 9 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Simard, John: 3 articles (01/2020 - 06/2015)
2.	Kurzrock, Razelle: 2 articles (01/2019 - 06/2015)
3.	Mohanty, Prasant: 2 articles (01/2019 - 06/2015)
4.	Stecher, Michael: 2 articles (01/2019 - 06/2015)
5.	Bamimore, Mary A: 1 article (06/2022)
6.	Gupta, Aditya K: 1 article (06/2022)
7.	Piguet, Vincent: 1 article (06/2022)
8.	Shear, Neil H: 1 article (06/2022)
9.	Babcock, Chad: 1 article (01/2020)
10.	Forman, Seth: 1 article (01/2020)

Related Diseases

1.	Hidradenitis Suppurativa 01/01/2022 - "Bermekimab achieved promising results in the treatment of hidradenitis suppurativa. " 01/01/2020 - "The objective of this study was to evaluate the safety and efficacy of bermekimab, an IL-1α inhibitor, in the treatment of hidradenitis suppurativa (HS). " 01/01/2020 - "A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain."
2.	Adenocarcinoma 11/04/2022 - "Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma." 09/02/2022 - "Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma."
3.	Pain (Aches) 01/01/2020 - "A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain." 06/01/2022 - "For pain reduction, infliximab was ranked most efficacious (SUCRA = 94%) compared to bermekimab, anakinra and placebo; infliximab reduced pain more significantly (p < .05) than anakinra and then placebo. "
4.	Neoplasms (Cancer) 12/01/2018 - "As such, IL-1α has been explored as a therapeutic target in cancer cachexia, leading to the development of bermekimab, a mAb which neutralizes IL-1α. " 12/01/2018 - "With a limited array of medication currently available to treat cancer cachexia, bermekimab represents a possible therapy. " 06/01/2015 - "Advanced non-small cell lung cancer (NSCLC) patients were treated as part of a Phase I dose escalation and expansion study evaluating a true human monoclonal antibody targeting IL-1α (Xilonix), which is intended to modulate the malignant phenotype-inhibiting tumor growth, spread and offering relief of symptoms. "
5.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2019 - "Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer." 01/01/2019 - "We investigated whether pre-treatment levels of circulating IL-1Ra, assessed by an enzyme-linked immunoassay, correlated with achievement of the primary outcome endpoint (effect on lean body mass and symptoms at week 8) in a Phase III study (2:1 randomization) of bermekimab versus placebo (each with best supportive care) in advanced colorectal cancer. " 01/01/2019 - "The current findings demonstrate that, in a randomized phase III trial, patients with advanced colorectal cancer and lower levels of circulating IL-1Ra are more responsive to treatment with the IL-1α-targeting antibody bermekimab and these observations define a potential biomarker for anti-IL-1α therapy."

Related Drugs and Biologics

1.	Leucovorin (Folinic Acid)
2.	Irinotecan (Camptosar)
3.	Interleukin 1 Receptor Antagonist Protein (Anakinra)
4.	Monoclonal Antibodies
5.	Interleukin-1 Receptors (Interleukin 1 Receptor)
6.	Biomarkers (Surrogate Marker)
7.	Fluorouracil (Carac)
8.	Enzymes
9.	Interleukin-1alpha (Interleukin 1 alpha)
10.	Cytokines

Related Therapies and Procedures

1.	Therapeutics